Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications.

By A. Wicki, D. Witzigmann, Vimalkumar Balasubramanian, J. Huwyler. Journal of Controlled Release, 2015

1,667 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Liposomal Formulations in Clinical Use: An Updated Review (2017, background): “LEM-ETU is a liposomal formulation entrapped with Mitoxantrone, composed of a 90:5:5 molar ratio of DOPC, cholesterol and cardiolipin [139].”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “…enhancing the efficacy and safety of chemotherapeutic agents for cancer treatment, many novel liposomal formulations are currently being investigated, some of which have already entered late stage clinical trials (Slingerland et al., 2012; May and Li, 2013; Oberoi et al., 2013; Wicki et al., 2015).”
The Smart Drug Delivery System and Its Clinical Potential (2016, background): “Despite the scope of nanomaterials are defined in the guidance, which is far from sufficient for nano-pharmaceutical industry [192].”